organ sale growth fairli line
forecast report revenu howev pressur greater currenc
headwind model lead slight top-lin miss devic sale
revenu beat estim grow despit linger weak vascular
neuromod clear momentum libr mitraclip show littl sign
slow segment competit challeng china hurt pediatr
nutrit busi manag assert trade war littl
impact abt overal busi sought-aft posit signal
compani tone today call remain bullish detail convey
fiscal manag project confid sustain revenu growth
overal trend appear consist us though light share
rel recent out-performance vs broader market surpris
in-lin result disappoint investor accustom beat
continu see littl risk execut recent expand share
buy-back program offer nice cushion ep howev feel premium
valuat abt comp group appropri reflect look ahead potenti
updat icgm approv reimburs fmr could nudg
share sens fewer opportun drive meaning upsid
near term maintain neutral rate
libr continu sweeten segment result diabet franchis grew
robust rate libr improv beat street
libr instal base continu grow reach user date
commentari around improv real-world outcom payor fervor
larg unchang compani continu expect uptick improv
expect hear icgm approv along result though
manag admit regulatori consent taken longer
expect unclear us fda requir data
growth impress lift world-wide sale growth
growth continu support improv penetr exist
account clinical/field sale expans compani remain track
open center goal expand time go forward
franchis benefit expans japan reimburs
expect end earli php compani confirm
shield ii trial remain activ admit enrol take longer
anticip due product tweak seem potenti approv might
push late earliest
valuat maintain neutral rate risk page
idc btig estim compani document
million except per share amount
abbott rate neutral recent year abbott share outperform peer overal market
last two year benefit solid pipelin launch high-growth area diabet diagnost
remain posit base busi see pathway toward drive high-singl digit revenu growth although
mitraclip still modest portion busi expect signific ramp follow label expans fmr
said share trade mid-teen premium comp group feel share rel valuat
abbott one largest
nutrit diagnost
stabl procedur growth price
expans current tam
cut reimburs
report revenu slightli street-high forecast constant currenc growth fairli in-
line forecast sizabl fx headwind pressur result vs model
devic result devic segment revenu consolid sale ahead street estim better diabet
ep result diabet sale consensu forecast libr sale y/i exceed
street estim sequenti libr sale grew libr perform continu bolster
favor payor trend strong demand back impress real-world data turn mitraclip sale
growth lift world-wide mitraclip growth neuromod revenu fell short consensu
forecast manag optimist recent initi enhanc salesforc bear fruit underli
spinal cord stimul market continu anem declin low-to-mid singl digit
segment turn diagnost organ sale growth led double-digit growth core lab
alin growth continu stellar europ report basi establish pharma perform weaker
forecast sale key emerg market includ india brazil russia china grew organ basi lastli
organ nutrit sale growth slightli ahead model perform broad-bas strong growth
seen asia latin america
profit metric gross margin forecast fx hurt sg spend
wors model offset came better estim tax rate
adj ep line forecast
actualsbtig estimate variancetot ebita ebitda incom net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
make chang revenu ep estim though adjust full-year forecast
slight miss greater fx headwind improv devic outlook rais estim
organ sale growth today currenc howev estim greater fx headwind
previous forecast depress report sale estim also flow neg impact
currenc gross margin trim adj ep estim slightli
abbott rate neutral recent year abbott share outperform peer overal market
last two year benefit solid pipelin launch high-growth area diabet diagnost
remain posit base busi see pathway toward drive high-singl digit revenu growth although
mitraclip still modest portion busi expect signific ramp label expans potenti
reimburs said share trade mid-teen premium comp group histor averag feel
share rel valuat appropri reflect risk vs reward
exhibit comp tabl large-cap peer
 net ep gross bpsadj ebit bp btig estim compani filingsnewold changecagrntm johnsonjnjnot fishertmobuy bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment y/i y/i y/i y/i y/i medic devic report pre-acqestablish pharmaceuticalkey emerg market y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growth oper adj y/i y/i growth y/i growth oper adj btig estim compani report
abbott segment devicesrhythm manag y/i manag y/i growth manag y/i growth y/i y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
